

REMARKS

Claims 1-5 and 8b are pending in this application and claims 6-7, 8a and 9-10 are withdrawn from consideration.

Claims 1, 4, 5 and 8b are being amended.

Upon entry of the present amendment, claims 1-5 and 8b remain pending in this application.

I. Claim Objections

Claims 8a and 8b have been objected to because the numbering of the claims is not in accordance with 37 CFR 1.126. The Applicants appreciate the Examiner's efforts in identifying the misnumbered claims. The misnumbered claims have been numbered 8a and 8b in the listing of claims provided above in the "Amendments to the Claims" section of this response. As such, the Applicants respectfully request that the objection to claims 8a and 8b be withdrawn.

II. Claim Rejections – 35 USC §112

The Office has rejected claims 1-5 and 8b under 35 U.S.C. 112, first paragraph, because the specification does not reasonably provide enablement for prodrugs.

In order to advance the prosecution of this application, the Applicants have deleted the prodrug language from claims 1, 4, 5 and 8b. As such, the Applicants respectfully request that the rejection of claims 1-5 and 8b be withdrawn.

III. Conclusion

Upon entry of the present amendments, the Applicants submit that this application is now in condition for allowance, which allowance is respectfully solicited.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at 734-622-2658.

Respectfully submitted,

Date: January 12, 2009

/Suzanne M. Bates/
Suzanne M. Bates
Attorney for Applicant
Registration No. 42,640

Pfizer Inc
Legal Division – Intellectual Property
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7656
Fax: (858) 678-8233